Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab extension and long-term observational study after parent Roche/Genentech trials
NL-OMON47480Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) and bladder cancer (3 arms), sponsored by Roche. Primary endpoint: Continued access to study treatment. Started Oct 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)bladder cancer
Beyond the preview
Go deeper on NL-OMON47480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47480.